Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] |
Feb. 27, 2026 |
|---|---|
| Subsequent Event [Line Items] | |
| Subsequent event, date | Feb. 27, 2026 |
| Subsequent event, description | On February 27, 2026, the Board of Directors (the “Board”) of the Company appointed Richard N. Kender, a current member of the Board, to serve as Executive Chair of the Board and as Interim Chief Executive Officer of the Company, Matthew Henn, Ph.D., the Company’s Chief Scientific Officer, to the additional role of President, and Kelly Brady, M.S., the Company’s Senior Vice President, Clinical Development, to the role of Executive Vice President, Chief Operating Officer, each effective March 2, 2026 (the “Effective Date”).As a result of the appointment of Mr. Kender as Interim Chief Executive Officer and Dr. Henn as President, Thomas J. DesRosier and Marella Thorell ceased serving as Co-Chief Executive Officers and Co-Presidents of the Company as of the Effective Date. Mr. DesRosier will continue to serve as the Company’s Executive Vice President, Chief Legal Officer, and Ms. Thorell will continue to serve as the Company’s Executive Vice President, Chief Financial Officer. |